
Nick Hughes
Founder
- Product and technical architecture
- Regulated clinical software and digital health development
- NHS pathway understanding
- Previously at Touch Surgery
Our team
Synovo is led by its two founders, advised by leading rheumatology academics at the University of Leeds, and used every day by clinicians at our sites in the UK and abroad.
Every feature is shaped with the doctors who care for people living with arthritis, so what you record at home is something your care team can trust.

94%correlation with DAS28, the clinic's own measure
97%Directional agreement when DAS28 changed by 0.6 points or more
3active clinical sites, in the UK, Pakistan and Bahrain
UKCAmarked medical device, registered with the MHRA
Founding team
One founder leads the product and technology, the other the clinical and commercial route to patients around the world.

Founder

Co-founder
Medical advisors
Rheumatology academics at the University of Leeds advise on study design, clinical evidence and how Synovo fits into patient care.

Medical Advisor, University of Leeds

Medical Advisor, University of Leeds
Clinical site leads
Clinicians at our active sites lead the day to day clinical work, from the NHS clinical audit to our international studies.

Clinical Lead, Bedfordshire

Clinical Lead, Pakistan

Clinical Lead, Bahrain
Strategic advisors
A small group advising on NHS adoption, investment and how we tell the Synovo story.

Strategic Advisor

Strategic Advisor

Strategic Advisor
For patients
Synovo is a UKCA marked medical device, developed with rheumatologists and checked against the measures used in clinic.
For investors
Clinical validation against DAS28, live NHS and international sites, and a team that spans medicine, regulated software and commercial growth.
The evidence
Measuring arthritis often, and acting on the results, leads to better outcomes. Research also shows it can be done safely at home, with fewer trips to hospital.
65% vs 16%
People whose arthritis was measured regularly and treated to a target reached remission far more often than those given routine care.
Grigor et al., The Lancet, 2004. The TICORA study, a randomised controlled trial.Read the study (opens in a new tab)Monthly
NICE advises measuring disease activity, using a score such as DAS28, every month until remission or low disease activity is reached.
NICE guideline NG100, 2018 (updated 2020). Rheumatoid arthritis in adults: management.Read the guideline (opens in a new tab)58% fewer
Following patients up remotely controlled their arthritis as well as clinic visits did, with far fewer face to face appointments.
de Thurah et al., Arthritis Care and Research, 2018. A randomised controlled trial of 294 patients.Read the study (opens in a new tab)20 million+
Over 20 million people, around a third of the UK, live with a musculoskeletal condition such as arthritis, putting real pressure on clinics.
Versus Arthritis (now Arthritis UK), 2023. The State of Musculoskeletal Health.Read the report (opens in a new tab)